GLPG 3667
Alternative Names: GLPG-3667Latest Information Update: 28 Mar 2025
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Dermatomyositis; Systemic lupus erythematosus
- No development reported Inflammation; Plaque psoriasis; Unspecified
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Canada
- 14 Mar 2025 GLPG 3667 is available for licensing as of 08 Jan 2025. https://www.glpg.com/contact/
- 28 Feb 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (PO, Capsule)